CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Stock
9 members of Congress disclosed 18 trades in CRL since 2018: 11 purchases and 7 sales, most recently Rob Bresnahan (sale, May 15, 2025). 4 of the hedge funds AlphaScala tracks reported CRL in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $270.70M. Company insiders reported 1 open-market buy and 9 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
Which members of Congress traded CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)?
Most recent: Rob Bresnahan (sale, May 15, 2025); records start Feb 13, 2018.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Rob Bresnahan R-PA · House | 2025-05-15 | sale | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-05-12 | sale | $15k – $50k |
| Jefferson Shreve R-IN · House | 2025-05-08 | purchase | $15k – $50k |
| Rob Bresnahan R-PA · House | 2025-04-08 | purchase | $15k – $50k |
| Julie Johnson D-TX · House | 2025-01-15 | purchase | $1k – $15k |
| Lois Frankel D-FL · House | 2023-09-08 | sale | $1k – $15k |
| Lois Frankel D-FL · House | 2023-04-25 | purchase | $1k – $15k |
| Zoe Lofgren D-CA · House | 2022-08-25 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all CRL political trades →Which hedge funds own CRL?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.19M | $270.70M | -2% |
| Millennium Management Israel Englander | 486K | $110.32M | -48% |
| Marshall Wace | 343K | $77.79M | +129% |
| D.E. Shaw David Shaw | 32K | $7.16M | -84% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are CHARLES RIVER LABORATORIES INTERNATIONAL, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 22, 26 | Foster James C | Director | SELL | 24.0K | $8.4M |
| Oct 21, 26 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | SELL | 2.2K | $743K |
| Oct 5, 26 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | SELL | 981 | $303K |
| Sep 30, 26 | Coleman Glenn | EVP & Chief Financial Officer | BUY | 10 | $3K |
| Aug 25, 26 | Foster James C | Director | SELL | 33.6K | $10.1M |
| Aug 19, 26 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | SELL | 2.0K | $600K |
| Aug 18, 26 | Andrews Nancy C | Director | SELL | 573 | $163K |
| Aug 11, 26 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | SELL | 3.7K | $1.0M |
| Aug 11, 26 | Girshick Birgit | Chief Executive Officer | SELL | 6.5K | $1.8M |
| Aug 10, 26 | Foster James C | Director | SELL | 28.7K | $7.9M |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →CRL price chart
Powered by TradingViewWhat does CHARLES RIVER LABORATORIES INTERNATIONAL, INC. do?
Charles River Laboratories International, Inc. is a leading provider of essential products and services that support pharmaceutical, biotechnology, and medical device companies in drug discovery, development, and manufacturing. It operates through three core segments: Research Models and Services, which supplies specialized animal models, insourcing solutions, and accelerator and development labs for preclinical research; Discovery and Safety Assessment, delivering regulatory-required safety testing for new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices; and Manufacturing Solutions, offering microbial solutions for in vitro testing and biologics solutions including testing services and avian vaccines. These offerings enable clients to advance therapies from early discovery through safety validation and production support, playing a critical role in the preclinical and clinical stages of the life sciences industry. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories International, Inc. serves a global market with a focus on high-quality, compliant research and testing services.